APGE — Apogee Therapeutics Balance Sheet
0.000.00%
- $4.23bn
- $3.70bn
- 34
- 19
- 63
- 31
Annual balance sheet for Apogee Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash | |||
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 152 | 395 | 521 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 152 | 398 | 530 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | — | 2.59 | 13.3 |
| Long Term Investments | |||
| Other Long Term Assets | |||
| Total Assets | 152 | 401 | 754 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Current Liabilities | 9.98 | 20.6 | 28.6 |
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 9.98 | 21.5 | 37.2 |
| Redeemable Preferred Stock | |||
| Non Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 142 | 380 | 717 |
| Total Liabilities & Shareholders' Equity | 152 | 401 | 754 |
| Total Common Shares Outstanding |